|
|
Biologic drug (biologics) Consumption in Czech Republic II
Farkašová, Veronika ; Horký, Pavel (advisor) ; Doseděl, Martin (referee)
Consumption of biologic drugs (biologics) in the Czech Republic Author: Veronika Farkašová Supervisor: doc. PharmDr. Jozef Malý, Ph.D. Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University Introduction: Biological treatment is modern alternative to chemotherapeutics especially in patients with difficult-to-treat diseases of autoimmune origin, as well as patients with other diseases as is cancer. They are heavily used in oncology for their wide range of indications. They are used as a monotherapy as well as in combination with traditional chemotherapy. Use of biological treatment can reduce the amount of treatment cycles of chemotherapy and reduce unwanted adverse effects. Objective: The aim of the diploma theasis was to analyze the consumption of biologigal treatment rituximab, bevacizumab, cetuximab and alemtuzumab. Methods: A retrospective analysis of the consumption of biosimilars rituximab, bevacizumab, cetuximab and alemtuzumab was performed from 1. 1. 2010 to 31. 12. 2020. The selection of specific biosimilars was made on the basis of their wide indication spectrum. Consumption data were obtained from the database of the State Institute for Drug Control (SÚKL). Descriptive statistics were used for the analysis. Consumption, given in the number...
|
guest ::
